Stockscreener 앱 받기
4.25
1.62%
-0.07
전일 마감가:
$4.32
열려 있는:
$4.36
하루 거래량:
234.46K
Relative Volume:
5.09
시가총액:
$128.68M
수익:
$15.33M
순이익/손실:
$-40.19M
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+4.42%
1개월 성능:
+4.42%
6개월 성능:
-43.78%
1년 성능:
+5.99%
1일 변동 폭
$4.1484
$4.36
1주일 범위
$4.06
$4.65
52주 변동 폭
$3.61
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
TLSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.25 | 128.68M | 15.33M | -40.19M | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World
Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada
TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Revenue Soars 42% in Q3, Expands into $375M Market | TLSI Stock News - StockTitan
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Q3 Earnings Estimate for TLSI Issued By Roth Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Roth Capital to "Strong-Buy" Rating - MarketBeat
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target By Investing.com - Investing.com South Africa
Roth/MKM starts TriSalus shares coverage with Buy rating, $11 target - Investing.com Canada
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Roth Mkm - MarketBeat
Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav - Business Wire
Reviewing TriSalus Life Sciences (TLSI) and Its Peers - Defense World
Critical Comparison: CARGO Therapeutics (CRGX) and Its Rivals - Defense World
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment - BioSpace
TriSalus Life Sciences (TLSI) to Release Quarterly Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Earnings on Thursday - MarketBeat
TriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on Thursday - Defense World
TriSalus Life Sciences® Inc. Launches TriNav® LV Infusion System and TriGuide? Guiding Catheters, Expanding Portfolio of PEDD? Devices for Improved Tumor Treatment - Marketscreener.com
TriSalus Life Sciences, Inc. Announces Resignation and Departure of Board Member and Chief Medical Officer - Defense World
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call - BioSpace
Northland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA - openPR
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in October - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Northland Capmk Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy" - MarketBeat
Northland initiates TriSalus shares with outperform, cites sales growth - Investing.com India
Northland initiates TriSalus shares with outperform, cites sales growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Northland Securities - MarketBeat
ALUS presents the 2024 Dave Reid Award to François Allard - GlobeNewswire Inc.
Riad Salem Joins Scientific Advisory Board Of TriSalus Life Sciences - MPO-mag
Riad Salem Joins Scientific Advisory Board of TriSalus Life Sciences - MPO-mag
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - BioSpace
Interventional Approaches for Locally Advanced Pancreatic Cancer - HMP Global Learning Network
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in September - MarketBeat
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
자본화:
|
볼륨(24시간):